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Background: Clinical targeting of TNFR family of receptors (CD40, CD134 and CD137) with immunostimulatory
monoclonal antibodies has been successful in cancer immunotherapy. However, targeting of CD27 with a mAb
is a relatively new approach to provide costimulation of immune cells undergoing activation. Thus, activation of
human CD27 (TNFRSF7) with a monoclonal antibody (varlilumab) has previously been demonstrated to result in T
cell activation and anti-tumor activity in preclinical models, and is currently in early phase clinical trials in patients
with advanced malignancies. In this study we used an in vitro system using human peripheral blood T cells to
characterize the varlilumab-mediated costimulatory effects in combination with TCR stimulation in terms of
phenotypic, transcriptional and functionality changes.
Methods: T cells were isolated from normal volunteer PBMCs using magnetic bead isolation kits and stimulated
in vitro with plate bound anti-CD3 Ab (OKT3) and varlilumab or control Ab for 72 h. Activation profiles were
monitored by ELISA or Luminex-based testing cytokine/chemokine releases, cell surface phenotyping for costimulatory
and coinhibitory markers and CFSE dye dilution by proliferating T cells and Tregs. Changes in gene expression and
transcriptome analysis of varlilumab-stimulated T cells was carried on Agilent Human whole genome microarray
datasets using a suite of statistical and bioinformatic software tools.
Results: Costimulation of T cells with varlilumab required continuous TCR signaling as pre-activated T cells were
unable to produce cytokines with CD27 signaling alone. Analysis of T cell subsets further revealed that memory
CD4+ and CD8+ T cells were specifically activated with a bias toward CD8+ T lymphocyte proliferation. Activation
was accompanied by upregulated cell surface expression of costimulatory [4-1BB, OX40, GITR and ICOS] and
coinhibitory [PD-1] molecules. Importantly, varlilumab costimulation did not activate purified Tregs as measured
by cytokine production, proliferation and suppression of dividing non-Treg T cells. Analysis of changes in gene
expression during varlilumab stimulation of T cells revealed modulation of pro-inflammatory signatures consistent with
cellular activation and proliferation, with the IL-2 pathway showing the highest frequency of gene modulation.
Conclusions: Altogether, the data reveal the requirements and T cell subtype-specific effects of CD27 costimulation,
and helps select relevant biomarkers for studying the effects of varlilumab in patients.
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CD27, a member of the TNFR superfamily (TNFRSF7),
is constitutively expressed as a costimulatory molecule
on naïve, activated and memory T cells, NK and NKT
cells, Treg and B lymphocytes. Its expression increases
upon T cell activation, and is lost at the fully differenti-
ated effector phase [1]. The ligand (CD70, CD27L) is
only transiently expressed in matured DCs and activated
T and B cells [2–4]. The CD27-CD70 axis appears to be
important in cell survival, maintenance of memory cell
function, anti-tumor cellular immunity and autoimmun-
ity [5–9]. Consistent with its role in T cell activation and
proliferation, CD27 costimulation improves the function
of T cells genetically engineered to express chimeric
antigen receptors (CARs) [10]. In humans, the role of
CD27 signaling in T cells is complex as it is unclear
whether the different lymphocyte subsets that express this
molecule are under the control of different transcription
factors or in a state of activation or differentiation.
Stimulatory and inhibitory signals are used to control
the threshold of T cell activation, survival, cytokine-
producing capacity and differentiation in a context
dependent manner [11]. A number of the costimulatory
molecules are members of the TNFSF/TNFRSF that cur-
rently consist of 19 ligands and 29 receptors expressed
by non-lymphoid and lymphoid cells [12]. T cells can
only translate signals through TNFRSFs in a TCR-
dependent manner to support costimulation, coinhi-
bition, proliferation, survival, cytolysis, polarization,
expansion of memory effectors and death [13, 14]. Util-
izing agonist mAbs to target select TNFR members has
proven an effective treatment modality in preclinical
cancer models [15–18], which has led to translational
clinical studies of agonist mAbs specific for CD40,
CD137, and OX40 [19–21].
Although the CD27 pathway has been studied less in
this context, a number of studies support that this TNFR
member may also be exploited for cancer immunother-
apy. Forced expression of CD70 in a transgenic mouse
model provides protection against an otherwise lethal
challenge of tumor cells by constitutive activation of the
CD27 pathway [22]. Furthermore, agonist mAbs specific
for mouse CD27 have shown efficacy against syngeneic
tumors [23, 24]. The anti-tumor activity of these anti-
CD27 mAbs was shown to require IFN-γ and is associ-
ated with an increase in effector cells in the tumor [25].
We have previously described the development and
characterization of an agonist fully human anti-CD27
mAb, varlilumab (also known by 1F5 or CDX-1127) [26,
27]. However, very little is known about a direct costi-
mulatory function of human T cells with the use of varli-
lumab. In this study we examine in more detail the
conditions of CD27 costimulation of in vitro activated
human T cells by varlilumab and show that the twosignals of activation must be presented concurrently to
support a regulatory role for this agonist anti-CD27
mAb that shapes transcriptional and translational
changes manifested as gene expression, pathway activa-
tion and biological function. These findings may have dir-
ect application to understanding the effects of varlilumab
in treated patients, and may clarify its effects as distinct
from the larger group of costimulatory mAbs in develop-
ment for activating immune responses against cancer.
Methods
Antibodies
Fully human anti-CD27 mAb (varlilumab; varli) was pro-
duced as previously described [25, 26], commercially
available monoclonal anti-human CD3ε (OKT3 clone,
eBioscience), ultra-LEAF Abs to 4-1BB, CD28, OX40,
GITR, superagonist anti-CD28 (CD28SA clone 28.2) and
isotype-matched control murine IgG1s were purchased
from BioLegend, control hIgG (fully human IgG1,
Celldex) and secondary goat anti-human LEAF Ab for
crosslinking were purchased from Southern Biotech
(Birmingham, AL). Mouse anti-human Abs to CD27
(M-T271), CD3, CD4, CD8, CD45RA, CD45RO (all from
BD Biosciences); mouse anti-huCD70 blocking Ab
(clone BU.69) was purchased from Abcam (UK).
Generation of CD70-293 and mock-293 transfectants
A vector containing the cDNA for human CD70 (acces-
sion # NM_001252.2) was purchased from Origene
(Rockville, MD). The DNA was digested with EcoRI and
NotI to release the fragment containing CD70, which
was inserted in the Origene vector pCMV6 (catalogue #
pS100009). The correct clone was confirmed by restric-
tion digest analysis and sequencing. FS-293 cells (a vari-
ant of HEK 293 cell line) were used for transfections
with the pCMV-CD70 (293-CD70) or pCMV-mock vec-
tor (293-mock) using the Invitrogen (Carlsbad, CA) re-
agents and following the manufacturer’s protocol. At
48 h post transfection, stable transfectants were selected
with G418 (0.5 mg/mL). Cell surface CD70 expression
was monitored by flow cytometry and high expressing
cell lines were selected for experiments.
Primary cell preparations and activation protocols
Freshly prepared buffy coats or whole blood were ob-
tained from normal healthy volunteers from a local
blood bank (Biological Specialty Corp., Colmar, PA) and
shipped within 2 h of collection in heparinized bags or
tubes. PBMCs were isolated by standard density gradient
centrifugation on Ficoll-Hypaque (Thermo-Fisher). T
cell purification was carried out by cell sorting on mag-
netic beads by negative selection (Human Pan T cell iso-
lation kit; Human Treg isolation kits (CD4/CD25hi/
FoxP3 and CD4/CD25hi/CD127dim) and CD3/CD4 or
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and used directly for in vitro stimulations. For stimula-
tion studies, multi-well culture plates were dry-coated
with various antibodies or antibody (Ab) combinations.
Unless otherwise noted, the concentrations of antibodies
used for coating were: OKT3 (1.0 μg/ml), varlilumab
(10 μg/ml), control hIgG1 (10 μg/ml), CD28SA (5 μg/ml).
Purified T cells (1 × 105 T cells/well) were added to wells
of a 96 well plate or 1.5 × 106 cells/well of a 24 well plate)
and stimulated with Abs for different durations from 24 to
72 h at 37 °C in a humidified CO2 incubator. Cells were
cultured in RPMI 1640 basal medium supplemented with
10 % heat-inactivated fetal bovine serum, L-Glutamine,
and penicillin/streptomycin. Cell-free culture supernatants
were obtained by centrifugation and frozen at −20 °C for
cytokine and biomarker analysis.
Analysis of cytokine production
Multi-well culture plates were dry-coated with OKT3
(1.0 μg/ml) and either varlilumab (10 μg/ml) or control
hIgG (10 μg/ml) prior to addition of T cells isolated
from individual donors. Cell culture supernatants were
collected from quadruplicate wells and pool tested for
cytokines in duplicate (IFNγ, IL-2, TNFα and IL-13) by
ELISA using commercial kits (R&D Systems) or with a
multiplexed Luminex bead-based assay (41-plex panel,
Eve Technologies, Calgary, Canada). Statistical treatment
of all cytokine/chemokine results was performed using
Student’s two-tailed paired t-test comparing varlilumab
costimulation with control stimulation; p values ≤ 0.05
were considered significant. The CV of replicate tests
was always less than 5 %.
Cell signaling pathway assay
T cells were stimulated for 72 h with OKT3/varlilumab
(Varli), OKT3/hIgG, or OKT3/anti-CD28 in the pres-
ence or absence of pathway-specific small molecule in-
hibitors (Invivogen, San Diego, CA). The inhibitors were
present for the duration of the experiment. The signaling
pathways were blocked with T cells pretreated with
NF-κB (Celastrol; 5 μM), MAPKK/ ERK1/2 (PD98059;
50 μM), PKR (2-Aminopurine; 5 μM), MAPK p38
(SB203580 10 μM), IκBα (BAY11-7082; 5 μM) and JAK2
(AG490; 50 μM). Supernatants were harvested from
quadruplicate wells and pooled for analysis of IFNγ pro-
duction by standard ELISA. All samples were run in du-
plicates with CV <5 %.
Gene expression analysis
T cells (1.5 × 106/well in 24 well plate) were stimu-
lated in vitro separately with two different protocols:
Set 1 (3 donors) was 72 h of continuous costimula-
tion (varlilumab/OKT3), while Set 2 (4 donors) was
46 h of pre-activation with OKT3 followed by 4 h ofcostimulation (varlilumab and OKT3 or isotype control
and OKT3). After stimulation, cell pellets were snap fro-
zen and processed for RNA extraction (Miltenyi RNA Iso-
lation Kit), QA/QC testing, and hybridization on Agilent
Whole Human Genome Oligo Microarrays (8 × 60K,
Miltenyi-Biotec, Auburn, CA). Raw data were processed
by FiosGenomics (Edinburgh, UK). The data sets were
background-corrected and normalized using quantile
normalization [28] from the green channel. Statistical
analysis was performed between the treatment groups
(varlilumab/OKT3 versus human IgG1/OKT3) within
each set using hypothesis testing based on empirical Bayes
[29] and correcting for false discovery rates using the
Benjamini-Hochberg method [30]. A congruence analysis
was performed between Set 1 and Set 2 to evaluate any
overlap between the two experiments. The evaluation of
congruence was performed at both the probe (gene) level
as well as the pathway (Gene Ontology/KEGG) level.
Differentially expressed genes were called at an adjusted
p-value <0.05. Heatmaps were generated by calculating
the log2 expression mean for each gene and subtracting
that from the iso and test data to yield a scale ranging
from −2 to +2 or another scale representing actual fold
changes unless otherwise noted. Genes were sorted ac-
cording to log2 fold changes. Heatmaps were created
using the MultiExperiment Viewer software (MeV) avail-
able in the TM4 Microarray Software Suite [31].
Accession code
NCBI Gene Expression Omnibus (GEO): microarray
data generated in this study are available in the link:
http://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE58267.
Intracellular cytokine staining (ICS)
ICS was used to define T cell subtypes involved in the
cytokine response to varlilumab costimulation. For these
studies, CD3+ T cells were preactivated with OKT3 for
46 h followed by 4 h of costimulation (varlilumab/OKT3).
The Cytofix/Cytoperm kit (BD Biosciences) was used for
ICS. Cells were treated with Brefeldin A (GolgiPlug™) for
4 h, and cytokines were stained with anti-IFNγ mAb after
permeabilization. The cell surface markers CD3, CD4,
CD8, CD69 and CD45RO were used to define T cell sub-
sets by staining with specific antibodies (BD Biosciences)
prior to analysis on a FACSCanto II instrument.
T cell proliferation assay
T cells (1 × 106/ml) were labeled with 0.5 μM carboxyflu-
orescein succinimidyl ester (CFSE, Life Technologies,
Carlsbad, CA) while rotating for 5 min. T cells (1 × 105
cells/well) were plated onto 96-well plates previously
coated with varlilumab or hIgG1 (2 μg/well) plus OKT3
(50 ng/well). Cells were then collected after 3 or 7 days
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analyzed by flow cytometry. The fluorochrome-
conjugated antibodies (BD Biosciences) were used to
stain for cell surface CD8, CD4, 4-1BB, OX40, PD-1,
ICOS, CD27 and CTLA-4. For Treg analysis purified
CD4 cells were cultured with dry-coated antibodies as
described and were fixed and detected using a Treg
FoxP3-based phenotyping kit following the manufac-
turer’s protocol (eBiosciences) and analyzed on a FACS-
Canto II instrument.
Results
Properties of varlilumab costimulation of T cells
We have previously shown that varlilumab can activate
human T cells in the context of TCR stimulation, but
only when the antibody is plate-bound to provide effect-
ive cross-linking [26]. We sought to investigate more
thoroughly the properties of varlilumab costimulation
through studies that investigated comparison to other
costimulatory pathways, kinetics of activation, breadth of
the cytokine response and signaling pathways. For these
studies we used purified T cells added to plates coated
with a suboptimal dose of OKT3 in a 3 day costimula-
tion assay using cytokine production as readout for acti-
vation. We initially showed that this method provides
effective costimulation through different TNFRSF mem-
bers- CD27, 4-1BB, OX40 and GITR (Fig. 1a). Analysis
of IFNγ responses using T cells from six donors showed
comparable costimulation with the CD27, 4–1 BB and
OX40 Abs, while a smaller increase was noted with
GITR Ab under these assay conditions.
We investigated the kinetics of costimulation for cyto-
kine production under these conditions, and found that
72 h was required to observe a high response to costi-
mulation, and that these kinetics were similar for each
cytokine analyzed (Fig. 1b). As shown with a representa-
tive donor, varlilumab treatment elicited significant
levels of the Th1 cytokines; IFNγ, IL-2, TNFα but also
high levels of the Th2 cytokine IL-13 from stimulated
cells in a time-dependent and specific manner as shown
with the isotype control Ab. To more fully characterize
the cytokine response under these conditions, cell cul-
ture supernatants were subjected to a cytokine/chemo-
kine analyses on a multiplex platform. The results show
a marked increase of Th1-like/inflammatory cytokines
and chemokines, some increases in Th2 cytokines
(predominantly IL-13 and IL-5) as well as induction of
several growth factors such as GM-CSF and CD40L
(see Additional file 1: A-C).
We did not initially expect the combined secretion of
IL-13 with the Th1 cytokines, and therefore investigated
whether a similar pattern would result from CD27 costi-
mulation of TCR-triggered T cells with its cognate
ligand, CD70. For these studies, T cells were culturedwith irradiated CD70-expressing or mock-transfected
cells in wells containing plate-bound OKT3. As shown,
similar to stimulation with varlilumab, T cell interaction
with CD70-293 cells but not mock-293 cells resulted in
release of high levels of IL-13 and IFNγ (Fig. 1c; p <
0.05). Specificity of this response was further shown by
blocking the response (in 2 out of 3 donors; p = 0.2) with
an anti-CD70 mIgG (BU.69) but not with an isotype-
matched control IgG.
We next addressed the question whether coincident
TCR signaling is critical for CD27-mediated costimula-
tion, or would pre-activated T cells be primed to re-
spond to varlilumab even in the absence of TCR
signaling. T cells were pre-activated by initial stimulation
for 46 h with OKT3 mAb alone and then transferred to
wells coated either with varlilumab or hIgG with or
without OKT3 mAb. In this format, T cell activation was
more rapid with high levels of IFNγ released within 24 h
(Fig. 1d). However, T cell activation still required both
TCR and CD27 signaling together, since the pre-
activated T cells could not be further stimulated with
varlilumab alone, emphasizing the requirement of con-
comitant TCR signaling at the time of CD27 costimula-
tion (n = 4; p = 0.09). Moreover, replacing TCR signaling
(OKT3) with CD28 stimulation or IL-2 did not result in
measurable costimulation with varlilumab (data not
shown) further demonstrating that complete activation
of T cells with varlilumab only ensues with continuous
TCR-triggering.
We also explored the effects of various signaling path-
way inhibitors on CD27 costimulation of T cells and
how they compared to CD28 costimulation using anti-
CD28 super agonistic mAb, CD28SA. As shown in
Fig. 1e lack of or reduction in IFNγ release by stimulated
T cells in the presence of inhibitors revealed that CD27
costimulation is coupled to 4 of 6 pathways tested
(NFκB, ERK1/2, PKR and IκBα signaling) thus resem-
bling pathways initiated by CD28 costimulation. In
contrast, however, TCR-triggered pathways utilizing
p38MAPkinase and JAK2 were less well intercepted with
inhibitors suggesting that these nodes are either not
playing a critical role or require participation of auxiliary
nodes. CD28 costimulation was distinct from that pro-
vided by CD27 in that CD28 only showed a partial in-
volvement of ERK1/2. These observations are consistent
with the expected pathways involved in co-stimulation
with TNFRSF members and show that T cells may utilize
canonical or non-canonical NFκB signaling pathways de-
pending on which costimulatory molecules are engaged.
Molecular footprinting of gene expression changes in
CD27 stimulated T cells
We next explored the molecular footprints of interacting
genes and pathways following CD27 costimulation. The
Fig. 1 Cytokine induction, kinetics and TCR dependence of anti-CD27 costimulation of T cells by varlilumab or natural ligand (CD70). T cells
were stimulated concurrently for 72 h with anti-CD3 (OKT3) and anti-CD27 (varlilumab; varli) antibodies. a Boxed whisker plot showing
direct comparison of varlilumab stimulation of T cells with that of 4-1BB, OX40 and GITR-specific Abs [n = 6]. Statistical comparisons of IFNγ
release by the different TNFR stimulations was performed using Welch Two Sample t-test; significance is shown as *p ≤ 0.05; **p ≤ 0.01.
b Cell culture supernatants were tested for Th1/Th2 cytokines at the time points indicated by standard ELISA; representative data of 3
donor samples is shown; c T cells were stimulated for 72 h with OKT3 and irradiated 293-CD70 or 293-mock cell lines and assessed for IFNγ and
IL-13. Additionally, CD70-dependent IFNγ release was assessed in the presence of a blocking Ab (BU.69) or control Ab (mIgG, left panel; n = 3) and
IL-13 (right panel; n = 4); d T cells were first pre-activated for 46 h with anti-CD3 and further stimulated with varlilumab or hIgG or in combination
with anti-CD3 for 24 h and tested for IFNγ (n = 4); NS, not significant (p = 0.09). e NFκB signaling by varlilumab-costimulated T cells for 72 h
showing differential release of IFNγ in the presence of known pathway-specific inhibitors (top to bottom)- NFκB (Celastrol), ERK1/2 (PD98059),
PKR (2-aminopurine), p38 MAPK (SB203580), IκBα (BAY11-7082), and JAK2 (AG490); bars represent mean ± SD (n = 4)
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sion in activated T cells was undertaken by hybridization
of labeled RNA onto commercially available human oli-
goarrays. T cells from multiple donors were analyzed
separately in paired fashion (varlilumab-treated versus
control hIgG-treated) using two separate protocols to
understand whether there were differences in “early”
versus “late” gene expression changes. Thus, T cells
were stimulated in a 3 day continuous OKT3/CD27
costimulation (Set 1 or late events) or a pre-activation
step with OKT3 alone followed by a OKT3/CD27 costi-
mulation for 4 h (Set 2 or early events). Molecularfingerprints of differentially expressed genes are visual-
ized with heatmaps showing log2 fold-changes in gene
expression patterns among top 25 genes up- or down-
regulated between varlilumab-stimulated (D1-D3 Varli)
versus control-stimulated (D1-D3 Iso) at 72 h (Set 1
Fig. 2a). Next we queried a list of highly enriched statis-
tically significant genes associated with inflammatory
signaling pathways. These are gene transcripts coding
for TNFRSFs, costimulatory (CD28/CTLA-Ig family)
and coinhibitory (immune checkpoint) molecules (Set 1,
Fig. 2b). A heatmap representation of this dataset shows
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Fig. 2 Transcriptome analysis showing changes in gene expression pattern during varlilumab costimulation of T cells. T cells were costimulated
continuously for 72 h (Set 1) or first preactivated with anti-CD3 (OKT3) for 46 h and costimulated briefly (4 h) with anti-CD3 + varlilumab or
anti-CD3 + control Ab (hIgG; Iso; Set 2). Treated cells were subjected to RNA extraction and hybridization on whole genome arrays as described.
a Heatmap showing log2 fold-changes as described under Methods shows the top 25 genes in red (upregulated) or blue (downregulated) during
varlilumab costimulation compared to isotype IgG stimulated controls in Set 1 protocol (n = 3). Log2 expression values were rescaled by calculating a
mean log2 expression for each gene and then subtracting that value from each individual gene expression value. This approach effectively centers the
gene expression values around zero so that actual fold changes are easily discerned from the heatmap (p < 0.05). b Select inflammatory panel gene list
queried to map transcripts coding for costimulatory (B7 family, TNFRSFs) and coinhibitory (immune checkpoint) molecules post varlilumab stimulation
(Set 1). Expression rescaling approach described above was also employed here. Gene symbols with asterisks are not significant (p > 0.05). All
other genes are significant according to non-adjusted p < 0.05. c Congruence plot showing varlilumab stimulation resulted in similar gene
expression signatures between Set 1 (n = 3) and Set 2 (n = 4) with 47 overlapped genes. Shown are log2 fold changes with an FDR-adjusted
p < 0.05. d Top 10 genes up/downregulated in response to Set 1 and Set 2 stimulation protocols, Shown are log2 fold changes with an FDR-
adjusted p < 0.05. e Fold-change in transcripts corresponding to cytokines, chemokines and growth factors. Heatmap shows log2 fold change
in gene expression comparing Set 1 and Set 2 type varlilumab stimulations. Heatmap representation was generated from an ordered gene list
so not all input genes are significant (shown with black asterisks) at pFDR < 0.05. Labels with red asterisks (IL6 and CCL5) were significant in
Set 1 with a direction of change being identical in both studies. All genes highlighted in (b, c and e) are significantly different in T cells stimulated with
varlilumab compared to isotype control Ab stimulations
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LAG-3, 4-1BB etc.) while other gene transcripts were
downregulated (CD27, CD28, KLRG1, OX40, GITR,
LIGHT etc.) following 72 h of varlilumab stimulation.Furthermore, genes represented in this heat map were de-
rived from an ordered genes-of-interest (GOI) list and
therefore contain significant as well as non-significant
gene signatures.
Table 2 KEGG pathways unique to set 2
Pathway ID Pathway name Direction
5332 Graft-versus-host disease Up
5145 Toxoplasmosis Up
5144 Malaria Up
5143 African trypanosomiasis Up
5142 Chagas disease (American trypanosomiasis) Up
4940 Type I diabetes mellitus Up
4664 Fc epsilon RI signaling pathway Up
4640 Hematopoietic cell lineage Up
524 Butirosin and neomycin biosynthesis Up
4350 TGF-beta signaling pathway Down
740 Riboflavin metabolism Down
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protocols (Set 1 and Set 2) to see if these methods were
influencing specific or common gene expression profiles.
Congruence analysis was performed by evaluating the
overlap between Set 1 (469 genes) and Set 2 (82 genes).
Overlaps were only considered if the fold changes were
also in the same direction. In total, 47 genes overlapped
between the two sets. This is significantly higher than
expected by chance (p = 1.358e-70) from a hyper-
geometric test. With respect to fold changes these are
generally quite consistent between the two sets as they
cluster around the diagonal. The main exceptions are
IL2 and B3GNT5 which are considerably higher in
Set 1 as well as RASGRP2 being considerably lower in
Set 1 compared to Set 2 when compared to control-
stimulation (Fig. 2c, Additional file 2). Enriched KEGG
pathways were also evaluated for overlaps across the two
sets, with 33 pathways in Set 1 and 19 pathways in Set 2.
A total of 8 KEGG pathways overlapped (Tables 1, 2 and
3; Additional file 2). This is significantly higher than ex-
pected by chance (p = 0.001943). In contrast, while
B3GNT5 a Golgi-resident aminotransferases involved in
mucin-type glycan biosynthesis was upregulated, the cal-
cium regulated T cell receptor pathway associated RAS
guanyl releasing protein 2 (RASGRP2) was suppressed.
Additional analysis included summarized fold-change
gene expression patterns for seven donors subjected toTable 1 KEGG pathways unique to set 1
Pathway ID Pathway name Direction
5146 Amoebiasis Up
5100 Bacterial invasion of epithelial cells Up
3320 PPAR signaling pathway Up
512 Mucin type O-Glycan biosynthesis Up
5416 Viral myocarditis Down
5332 Graft-versus-host disease Down
5322 Systemic lupus erythematosus Down




4940 Type I diabetes mellitus Down
4916 Melanogenesis Down
4710 Circadian rhythm - mammal Down
4640 Hematopoietic cell lineage Down
4612 Antigen processing and presentation Down
4514 Cell adhesion molecules (CAMs) Down
4145 Phagosome Down
4144 Endocytosis Down
4062 Chemokine signaling pathway DownSet 1 and Set 2 treatments over Iso controls. Thus, log2
expression data significant at p < 0.05 were generated
and mapped to list the top 10 genes regulated up/down
(Fig. 2d). In addition, log2 fold changes and scaled ex-
pression of cytokine-chemokine gene signatures were
mapped from a GOI list and contain both significant
and non-significant gene signatures (Fig. 2e). Analysis of
differentially expressed enriched gene categories and cu-
rated pathways showed IL-2 pathway to be highly popu-
lated with gene targets compared to other signaling
pathways (Fig. 3) of which substantially greater number
of genes to be induced rather than repressed (Table 4).
CD27 costimulation supports proliferation and cytokine
production from specific T cell subsets
Functional analysis of T cells co-activated by TCR and
CD27 was extended to study proliferative responses and
intracellular cytokine staining. CFSE dye-labeled T cells
showed a remarkable level of proliferation specifically in
response to varlilumab costimulation with the great ma-
jority of cells undergoing division by day 7 of culture
(Fig. 4a). Due to the production of IL-2 and other cyto-
kines, it is likely that some of the proliferation observed
at day 7 is due to indirect effects rather than through
direct CD27 costimulation. Interestingly, varlilumabTable 3 KEGG pathways overlapping set 1 and set 2
Pathway ID Pathway name Direction
5330 Allograft rejection Up
5320 Autoimmune thyroid disease Up
5310 Asthma Up
4672 Intestinal immune network for IgA production Up
4660 T cell receptor signaling pathway Up
4630 Jak-STAT signaling pathway Up
4060 Cytokine-cytokine receptor interaction Up
5323 Rheumatoid arthritis Down
Fig. 3 Pathways differentially affected by varlilumab costimulation. A bar chart showing the frequency of representative categories within the
gene list (Varlilumab/Test versus Control/Iso/ hIgG_Stringent DGA) with functional grouping. Size of bars denotes the number of genes/targets
populating the pathway and independent of the importance of any pathway relative to other pathways. Data were curated on Miltenyi-Biotec’s
database of annotated and enriched pathway targets. Numbers in parenthesis refer to number of genes/targets either induced (upregulated) or
repressed (downregulated) in the pathway(s) relative to control. DGA, Differential Gene Expression Analysis
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to CD4 T cells (47 % CD8 dividing cells versus 29 %
CD4 cells at day 3 and 91 % dividing CD8 T cells versus
73 % CD4 T cells at day 7). The T cells costimulated with
varlilumab for 3 days were further characterized for ex-
pression of costimulatory and inhibitory molecules that
are characteristic of activated T cells (Fig. 4b). Thus, sig-
nificant upregulation of OX-40, GITR, PD-1, 4-1BB and
ICOS was observed on both CD4 and CD8 populations
of T cells and preferentially on the dividing cells, consist-
ent with an activated T cell phenotype. We further in-
vestigated the T cell subpopulations most responsive to
CD27 costimulation with varlilumab. For these studies
we pre-activated T cells with OKT3 in order to observe
the early response to CD27 costimulation (4 h) by ICS
(Fig. 5a and b). Among CD4 T cells, we detected asignificant increase in the number of CD69+ IFNγ+
primarily in CD45RO+ (memory) cells. Among CD8 T
cells, both CD45RO+ and CD45RO– cells showed an in-
crease in IFNγ production.
Tregs are known to express CD27, but the role of CD27
costimulation on these cells and their function is unknown.
To this end, we explored the effect of CD27 costimulation
on Tregs relative to other T cells. As shown in Fig. 6a puri-
fied Tregs exposed to 3 days of costimulation with varlilu-
mab and OKT3 did not result in detectable level of IFNγ
or IL-10 secretion. However, costimulation using OKT3
and anti-CD28 showed the capacity of the Treg to produce
large amounts of IL-10 and to a lesser extent IFNγ. Import-
antly, the conventional T cells (i.e. non-Tregs) from the
same donors showed the expected high level of IFNγ pro-
duction and low IL-10 secretion upon CD27 costimulation.
Table 4 IL-2 pathway genes modulated by Varlilumab




IL1RAP Interleukin 1 receptor accessory protein
IL13 Interleukin 13
ADD2 Adducin 2 (beta)
CTNNA1 Catenin (cadherin-associated protein) alpha 1
TERT Telomerase reverse transcriptase
LAIR2 Leukocyte-associated Ig-like receptor 2
MYC v-myc Myelocytomatosis viral oncogene homolog
(avian)
LIF Leukemia inhibitory factor
DUSP6 Dual specificity phosphatase 6
OSM Oncostatin M
CSF2 Colony stimulating factor 2 (granulocyte-macrophage)
IER3 Immediate early response 3
CSF1 Colony stimulating factor 1 (macrophage)
NTRK1 Neurotrophic tyrosine kinase receptor type 1
NFIL3 Nuclear factor, interleukin 3 regulated
IL5 Interleukin 5
GZMB Granzyme B (granzyme 2, CTL-associated serine esterase 1
XCL1 Chemokine (C motif) ligand 1




PRSS23 Protease serine 23
PHLDB2 Pleckstrin homology-like domain, family B,
member 2
Repressed pathway genes
CXCR5 Chemokine (C-X-C motif) receptor 5
MYC v-myc Myelocytomatosis viral oncogene homolog
(avian)
APP Amyloid beta (A4) precursor protein
IL24 Interleukin 24
Ramakrishna et al. Journal for ImmunoTherapy of Cancer  (2015) 3:37 Page 9 of 13We also examined proliferation of the Treg subset by flow
cytometry, and did observe some proliferation among
Tregs during CD27 costimulation (Fig. 6b upper left gate).
However, this was relatively low compared to the FoxP3− T
cell populations (lower gate), and may be the result of IL-2
production by activated non-Tregs.
Discussion
The TNFR superfamily of proteins has gained consider-
able attention in the last decade with a surge in develop-
ment of immunomodulatory biologics to treat cancer,infectious diseases and autoimmunity. Targeting signal-
ing molecules to enhance anti-cancer immunity has fo-
cused on two approaches: (a) activating costimulatory
molecules with agonistic Abs directed to T cell surface
molecules- CD27, CD40, OX40 and CD137; or (b)
blockade of inhibitory pathways with monoclonal Abs
directed to cell surface CTLA-4, PD-1/PD-L1, TIM-3,
BTLA and LAG-3 [32]. From a clinical perspective,
more progress has been achieved with blockade of in-
hibitory pathways than with the agonist mAbs. This is at
least partially due to the fundamental safety challenges
of triggering potent costimulatory pathways, which was
exemplified by the experience using an anti-CD28 mAb
[33], and dose-limiting toxicities for the development of
mAbs to CD40 and CD137 have also been reported
[19, 20]. To implement effective costimulatory strat-
egies in the clinic, further characterization and under-
standing of these agents and their effects is required.
In the case of CD27, the development of mAbs with
costimulatory activity is further complicated by data that
support the potential anticancer effects of antagonizing
this pathway. For example, overexpression of CD70 by
tumor cells has been shown to promote T cell dys-
function or apoptosis through CD27 signaling in vitro
[34, 35]. However, this effect was overridden by the
immune activating properties of CD27 signaling when
tested in tumor models [36]. In addition, CD27 sig-
naling in Treg (discussed further below) has been im-
plicated as a means of tumor escape [37], further
emphasizing the need to fully characterize the func-
tional activity of CD27 agonist mAbs. In this study
we sought to better characterize the costimulatory
properties of varlilumab, the first anti-CD27 mAb to
enter clinical trials for treatment of lymphomas and
solid tumors. Our analysis was mainly conducted on
T cells isolated from healthy individuals, cultured
under controlled conditions, and demonstrated a ro-
bust activation when varlilumab is combined with
TCR stimulation. This study did not analyze other
CD27-expressing immune cells such as NK or B cell
subsets. The majority of circulating NK cells does not ex-
press significant levels of CD27, and our preliminary re-
sults suggest that varlilumab does not have a significant
effect on circulating B cells (data not shown).
Initially, we compared varlilumab to commercially avail-
able Abs to 4-1-BB, GITR and OX40 in the ability to elicit
IFNγ production under one standardized condition. Thus,
T cell CD27 costimulation with varlilumab was compar-
able to anti-4-1BB, anti-OX40 costimulations but to a
lesser extent with anti-GITR Abs. This study was not
meant as a comprehensive comparison of these related
costimulatory molecules, but rather as a demonstration
that the conditions used in our study are relevant to other
related TNFRSF members. Important to the mechanism
Fig. 4 Induced proliferations of T cell subsets and coexpression of costimulatory and coinhibitory receptors (immune checkpoint molecules).
Differences in short term (3 day) or long term (7 day) T cell cultures undergoing stimulations with varlilumab or control antibody (hIgG) show
more CD8+ cells (a) entering the division cycle in the varlilumab-treated group. Numbers in the histograms refer to the percent of indicated
cells (CD8+ or CD3+CD8-) that are dividing as reflected by CFSE staining (a bottom panel). b CD27+ proliferating CD4+ and CD8+ T cells were
stained with antibodies to additional cell surface markers representing costimulatory (GITR, OX40, ICOS and 4-1BB) and coinhibitory (PD-1) molecules.
Dividing CD8+ and CD4+ T cells show marked upregulation of costimulatory and coinhibitory molecules relative to non-dividing cells. Shaded
histograms represent T cells stimulated with control antibody and anti-CD3 (OKT3). Numbers in the histograms refer to percent of T cells (dividing or
non-dividing CD8 or CD4 cells) that are positive for the indicated costimulatory or coinhibitory marker (b)
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must be provided simultaneously with CD27 activation,
even in pre-activated T cells in order to result in effect-
ive stimulation as measured by cytokine secretion.
The cytokine response to varlilumab costimulated T
cells was characterized to include high levels of Th1 cy-
tokines (IFNγ, TNFα, and IL-2), and also significant in-
duction of some Th2 cytokines, dominated by IL-13.
This pattern was not unique to costimulation of CD27
with varlilumab, as we observed similar IFNγ and IL-13
secretion from T cells activated with the CD27 ligand,
CD70. A similar pattern of Th1 cytokines and IL-13 se-
cretion has been reported for a CD137 agonist mAb,
and thus may represent a general feature of TNFR costi-
mulation. In this study IL-13 secretion has been thought
to provide a feedback mechanism to dampen excessive
inflammation [38].
To understand whether CD27 downstream events of
cytokine production were dependent on canonical or
alternate NFkB signaling, T cells were stimulated in the
presence of pathway–specific inhibitors. These experi-
ments revealed that IFNγ production was compromisedin the presence of JAK2, ERK1/2 and PKR signaling in-
hibitors which somewhat overlapped with CD28 signal-
ing and consistent with previous reports on CD27
signaling pathways [39, 40]. We also explored the
changes in gene expression and signaling pathways fol-
lowing CD27 costimulation. Significant regulation of
other TNFRSF members, cytokines and other immune
related markers was observed, and genes in the IL-2 sig-
naling pathway were most significantly affected consist-
ent with studies previously reported by Peperzak et al.
[41]. While the microarray technology allows for a rapid
high throughput and high content analysis of gene ex-
pression in in vitro stimulated cells it only provides a
snapshot of subtle/marked changes in transcriptional
levels of genes and targets implicated in functional cell
signaling pathways. The information obtained must
therefore be interpreted with caution as it is not uncom-
mon to find a lack of correspondence between transcrip-
tional events and protein expression.
To gain insight into specific populations of T cells
responding to CD27 costimulation, we used flow cytom-
etry to measure proliferation and cytokine production
Fig. 5 Early detection of cytokines by varlilumab costimulated T cell subsets. T cells were preactivated with OKT3 for 46 h and post activated for
4 h with OKT3+ varlilumab or OKT3+ hIgG. Intracellular staining for IFNγ response in different T cell subpopulations (a) Naïve CD4+ (CD45RO ̶)
and memory (CD45RO+) and (b) naïve CD8+ (CD45RO ̶) and memory (CD45RO+) T cells. Cells were co-stained for the activation marker CD69.
Numbers in individual plots refer to percent IFNγ+ cells
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induced potent proliferation of both CD8+ and CD8- T
cells, but its effect was greatest on the CD8+ T cells.
This appears to be due to the responsiveness of both
CD45RO+ and CD45RO- subsets of CD8 T cells, whileFig. 6 Conventional T cells, but not CD4+CD25hiFoxP3+ (Tregs), can be stim
isolated Tregs (CD4+/CD25hi/FoxP3+) were compared with CD3+ T cells from
OKT3/CD28 or OKT3/control IgG; and b CFSE-labeled OKT3-activated and varlilu
subset was then plotted by CFSE and FoxP3. Rectangular gates were drawn to
rectangular), and FoxP3+ dividing (upper-left rectangular), subsetsonly those CD4 T cells with the memory phenotype were
stimulated under these conditions. The observed differ-
ences were not likely due to differential CD27 surface ex-
pression among T subsets since we observed lowest basal
CD27 expression on the CD45RO+ cells (see Additionalulated by varlilumab to produce cytokines and proliferate. Magnetically
the same donor a for their response to stimulation with OKT3/varlilumab,
mab stimulated pan T cells were first gated on CD4+CD25+ subset, this
indicate FoxP3- (lower rectangular), FoxP3+ non-dividing (upper-right
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acity of these cell populations to become activated in vitro
and the variable expression of inhibitory receptors may
also account for the observed differential proliferative cap-
acity of CD8s versus CD4s. The fate of cells activated by
anti-CD3 and a costimulatory molecule often is accom-
panied by upregulation of accessory molecules that either
amplify or dampen the existing response. Interestingly, we
have observed extended coexpression of 4-1BB, GITR,
OX40, ICOS, CTLA-4 and PD-1 believed to be associated
with CD27 triggering in presence of TCR triggering. The
discordance of some of these changes with the gene ex-
pression data is unclear at present but suggest a more
complex network of genes being co-regulated that could
affect kinetics of biomarker availability on the cell surface.
CD27 is expressed constitutively on human Tregs [42]
and CD27 co-stimulation in the thymus rescues develop-
ing Treg cells from apoptosis and thereby promotes Treg
generation [43]. CD27 signaling has also been implicated
in Treg expansion in mice] where increased numbers of
Tregs in tumor infiltrating lymphocytes, spleens and
nodes were reported in CD27(+/+) wild type mice rela-
tive to CD27(−/−) mice suggesting that CD27-CD70
signaling increases the number of Tregs [37]. Because a
comparison of mice completely lacking CD27 compared
to those simply expressing CD27 is not necessarily
representative of the effects of a particular agonist
anti-CD27 mAb, we therefore explored the effect of var-
lilumab costimulation on proliferation and cytokine pro-
duction on purified Treg cells. We showed that cytokine
induction and stimulation of proliferation by varlilumab
were much lower for Tregs than for conventional T cells,
and much lower than that induced by anti-CD28 as well.
This suggests that CD27 and CD28 may follow divergent
pathways in Treg stimulation and is consistent with other
reports on Treg costimulation requirements [44, 45]. Our
in vitro results using human T cells are consistent with
mouse tumor model studies in which an agonist anti-
mouse CD27 mAb (AT124-1) reduced the numbers of
FoxP3-expressing cells within tumors but had no effect on
the suppressor activity on a per cell basis [25]. Our
in vitro results are also consistent with our early clinical
results [46] in which treatment with varlilumab leads to a
significant and roughly 50 % reduction in Tregs in the
peripheral circulation. While this does not preclude the
potential benefit of antagonizing the CD27 pathway as has
been proposed by others [47], the cumulative data with
our agonist mAb, varlilumab, does not support the occur-
rence of unwanted Treg activation.Conclusions
Altogether, this study documents the requirements,
kinetics and breadth of the in vitro T cell activationsignature with varlilumab costimulation through CD27.
Consistent with earlier studies, the data demonstrate a
tightly regulated response that includes both immune
potentiating and immune regulating changes. These mo-
lecular and cellular patterns should predict biomarkers
that may be impacted in patients treated with varlilu-
mab. Correlations of these markers with the safety and
clinical benefit from varlilumab treatment is ongoing
and will be important to better understand which fea-
tures of CD27 costimulation are most relevant to out-
comes seen in patients.
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